Skip to content

Trial · Interventional

CompletedPhase 1Registry data

ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability

NCTNCT04561245 (opens ClinicalTrials.gov in a new tab)Other idALT-801-101Other idPemvidutide

Overview

Status
Completed
Phase
Phase 1
Enrollment
100 participants (actual)
Sponsor
Altimmune, Inc. · Industry
Design
Randomized · Double masking
Countries
1 country

Australia

Start
10 Nov 2020
Primary completion
29 Oct 2021
Completion
29 Oct 2021
First posted
23 Sept 2020
Last update posted
24 Jun 2025
Conditions
Obesity · Nonalcoholic Steatohepatitis

Timeline

1 trial · 1 completed

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
202020212022
  1. Ph 1

    ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability

    NCT04561245

    10 Nov 2020 to 29 Oct 2021

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

This study was a FIH, Phase 1, randomized, double-blind, placebo-controlled, 2-part single-ascending dose (SAD) and multiple-ascending dose (MAD) study of ALT-801 (pemvidutide) in healthy overweight and obese subjects. The purpose of the study was to assess the safety and tolerability in healthy overweight and obese volunteers administered single or multiple repeated doses of ALT-801 (pemvidutide).

Interventions

  • ALT-801Drug
  • PlaceboOther

Arms4

  • Experimental

    ALT-801 (Part 1)

    Single ascending dose (SAD) cohorts of ALT-801

  • Placebo comparator

    Placebo (Part 1)

    Single dose of placebo

  • Experimental

    ALT-801 (Part 2)

    Multiple ascending dose (MAD) cohorts of ALT-801 administered once weekly for 12 weeks

  • Placebo comparator

    Placebo (Part 2)

    Placebo administered once weekly for 12 weeks

Primary outcomes5

Outcomes the sponsor listed as primary.

  1. The Number of Participants with One or More Treatment-Emergent Adverse Events (TEAEs)

    Time frame · Part 1 SAD Cohorts: up to Day 26; Part 2 MAD Cohorts: up to Day 42

  2. Pharmacokinetic (PK): Maximum observed concentration (Cmax) of ALT-801

    Time frame · Baseline, Day 26

  3. Pharmacokinetic (PK): Area Under the Concentration (AUC) vs Time Curve of ALT-801

    Time frame · Baseline to Day 26

  4. Change in body weight

    Time frame · Baseline to Week 6

  5. Pharmacodynamic (PD): Change from baseline in magnetic resonance derived proton density fat fraction (MRI-PDFF)

    Time frame · Baseline to Week 6

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

Completed trials do not always post results.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies0

Studies that cite this trial.

No study cites this trial.

Eligibility

Who could join, as posted.

Sex
All
Age
from 18 Years up to 60 Years
Healthy volunteers
Accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Male or female healthy volunteers, age 18 to 60 years, inclusive * Overweight to obese (BMI 25.0 - 40.0 kg/m2) * MRI-PDFF≥ 10% (Part 2 only) * Non-smokers or ex-smokers (must have ceased smoking \> 1 months prior to screening visit) * Subjects must otherwise be in good general health, with no significant medical history, have no clinically significant abnormalities on physical examination at screening, and/or before administration of the initial dose of study medication * Ability and willingness to attend the necessary visits to the study center * Written informed consent signed prior to entry into the study Exclusion Criteria: * Women who are pregnant or breastfeeding * History of pancreatitis * History of or acute significant GI disorder * History of diabetes or use of medications for the treatment of diabetes, or hyperglycemia or HbA1c ≥ 6.5% * History of clinically significant endocrine (eg, hypothyroidism), neurological, GI, cardiovascular (except controlled hypertension and hypercholesterolemia), hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases * History of neoplastic disease, or personal or family history of multiple endocrine neoplasia or medullary cancer of the thyroid, with the following exceptions: 1. Adequately treated non-melanomatous skin carcinoma 2. Female with a history of benign cervical neoplasia if the subject has been compliant with surveillance and treatment as recommended by her physician * Blood pressure \> 150/90 mmHg or heart rate \> 100 beats per minute at screening and at Day -1 * Clinically significant laboratory abnormalities including: Impaired renal function (estimated glomerular filtration rate \[eGFR\] \<60 mL/min/1.73m2) as estimated using the MDRD equation at screening: 1. GFR (mL/min/1.73 m²) = 175 × (SCr/88.4)-1.154 × (Age)-0.203 × (0.742 if female) × (1.212 if African American) (SI units), where SCr is standardized serum creatinine in SI units (µmol/L) and age is in years 2. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) laboratory values \> 2 × upper normal limits 3. Calcitonin \> 50 ng/L - Excessive alcohol consumption defined as \>21 alcohol units per week for males and as \>14 alcohol units per week for females (where 1 unit = half pint of beer, 25 mL of 40% spirit, or 125 mL of wine)

PepBank is a research reference. Talk to a doctor before you use any peptide.